Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

HK CEO/Director Dealings (22 Sep 2025): TYK Medicine, Chanjet's Full Circulation, Bonjour, Shunten

HK CEO & Director Dealings (28th Feb 2025): Mobvista, Xtep, Onewo, Bonny International

HK CEO & Director Dealings (31st Dec 2024): Weimob Inc., Midea Real Estate, Pharmaron Beijing

Quiddity Advisors

Event-Driven

<ul>
<li>The data in this insight is collated from the "shareholding disclosure" link on the HKEx website.</li>
<li>Often there is a corresponding HKEx announcement on the increase - or decrease - in the shareholding by directors. </li>
<li>However, such disclosures are by no means an absolute. These insights also flag those companies where shares have been pledged, both recently and ongoing.</li>
</ul>


The data in this insight is collated from the "shareholding disclosure" link on the HKEx website.
Often there is a corresponding HKEx announcement on the increase - or decrease - in the shareholding by directors. 
However, such disclosures are by no means an absolute. These insights also flag those companies where shares have been pledged, both recently and ongoing.


AuGroup Shenzhen Cross-Border Business (2519 HK)

HK CEO/Director Dealings (31 Oct 2025): Shanghai Chicmax, AuGroup (Shenzhen), Twintek, Rongzun

Shanghai Chicmax Cosmetic

HK CEO/Director Dealings (31 Oct 2025): Shanghai Chicmax, AuGroup (Shenzhen), Twintek, Rongzun